Li N Zeng

US Patent:

20120321553, Dec 20, 2012

Filed:

May 1, 2012

Appl. No.:

13/461307

Inventors:

Li Zeng - Edison NJ, US
Rohini Mitra - Brigdewater NJ, US
Edmund A. Rossi - Woodland Park NJ, US
Hans J. Hansen - Picayune MS, US
David M. Goldenberg - Mendham NJ, US

Assignee:

IMMUNOMEDICS, INC. - Morris Plains NJ

International Classification:

A61K 39/395
A61P 37/00
A61P 31/00
A61P 35/00
A61P 3/00
A61P 25/28
A61P 3/10
A61P 9/00
A61P 25/00
A61K 51/00
A61P 35/02

US Classification:

424 111, 4241301, 4241411, 4241361, 4241331, 4241781, 4241341, 424 851, 424 852, 424 854, 424 857, 424 856, 424 855, 4241581, 4241721, 4241381

Abstract:

Disclosed are methods, compositions and uses of high concentration antibody or immunoglobulin formulations for subcutaneous, intramuscular, transdermal or other local (regional) administration, in a volume of than 3, less than 2 or less than 1 ml. Preferably, the formulation contains a high concentration formulation (HCF) buffer comprising phosphate, citrate, polysorbate 80 and mannitol at a pH of about 5.2. The formulation more preferably comprises at least 100, 150, 200, 250 mg/ml or 300 mg/ml of antibody. The methods for preparing the high concentration formulation include ultrafiltration and diafiltration to concentrate the antibody and exchange the medium for HCF buffer. Other embodiments concern use of non-G1m1 (nG1m1) allotype antibodies, such as G1m3 and/or a nG1m1,2 antibodies. The nG1m1 antibodies show decreased immunogenicity compared to G1m1 antibodies.

US Patent:

63070197, Oct 23, 2001

Filed:

Jul 10, 1997

Appl. No.:

8/890865

Inventors:

Franklin Constantini - New York NY
Li Zeng - New York NY

Assignee:

The Trustees of Columbia University in the City of New York - New York NY

International Classification:

C07K 1400
C07H 2102
C07H 2104
C12P 2106

US Classification:

530350

Abstract:

This invention provides an isolated nucleic acid which encodes Axin. This invention further provides an isolated nucleic acid which encodes a polypeptide comprising the amino acid sequence of Axin. This invention further provides a purified wildtype or mutant Axin. This invention further provides an oligonucleotide capable of distinguishing nucleic acids encoding mutant or wildtype Axin. This invention also provides various methods of use: such as a method for determining whether a subject carries a mutation in the axin gene, a method of determining whether a subject has a predisposition for cancer, a method for treating a subject who has a predisposition to cancer, a method for determining whether a subject has cancer, a method for detecting a mutation in cancerous cells of the subject, a method of suppressing cells unable to regulate themselves and a method for identifying a chemical compound which is capable of suppressing cells unable to regulate themselves. This invention also provides a variety of pharmaceutical compositions and a method of treating a subject who has cancer comprising administration the pharmaceutical compositions. This invention also provides a transgenic, nonhuman mammal, specifically a transgenic expressing mutant Axin.